Morgan Stanley raised the firm’s price target on AbbVie (ABBV) to $250 from $241 and keeps an Overweight rating on the shares. While aesthetics remains soft and potential pharma tariffs remain an overhang on the stock, AbbVie reported “another solid quarter for the immunology franchise,” with a Q1 beat and raised 2025 guidance, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie Stock (ABBV) Up 8% on the Week as Company Soars Past Q1 Expectations
- AbbVie Reports Strong Q1 2025 Financial Results
- AbbVie Earnings Call: Strong Growth Amid Challenges
- S&P 500 Index Today: Earnings Beats Boost the SPX
- China weighs U.S. tariff exemptions, Alphabet reports Q1 beat: Morning Buzz